Thermosome is an emerging biopharmaceutical company headquartered in the Innovation and Start-Up Center for Biotechnology (IZB) in Planegg/Martinsried near Munich, Germany. Our technology was invented by Prof. Dr. Hansjörg Eibl at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, and applied, among others, in various in vitro and in vivo studies by a research group at the University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany. Based on inspiring results from this research including the preclinical proof-of-concept in various animal species, Thermosome started its operational activities in late 2015.
who we are
Thermosome is dedicated to significantly enlarging the therapeutic and safety window of active pharmaceutical ingredients (API)
Thermosome intends to leverage its proprietary drug delivery technology for own and partnered drug development. Our key aims are to:
Thermosome’s vision is to leverage our novel platform technology to significantly enlarging the therapeutic and safety window of the encapsulated drugs and reach both improved therapeutic outcomes and improved quality of life in patients. We aim to give the encapsulated drugs a completely new pharmaceutical quality through our novel, innovative delivery technique. We are working hard to one day realize our long-term aim: adding new and clinically validated treatment options to patients with serious diseases such as cancer.
We are financed by a consortium of venture capital funds and private investors, comprising, among others, High-Tech Gründerfonds (HTGF) and Bayern Kapital, and received substantial, multi-year grant funding from the German Federal Ministry of Education and Research (BMBF) of the Federal Republic of Germany. The setup is complemented by a strong network of both national and international industry and academic partners.